title: Understanding tumor profiling and assessing treatment.
abstract: Gene expression profiling allows us to look into a tumor cell to see how genetic information is communicated and affects cell behavior. Data gathered during the development of the 70-gene assay (MammaPrint) set the stage for future assay development. Recently, a 21-gene assay (Oncotype DX) was recommended by ASCO and NCCN as a standard of care for newly diagnosed, stage 1 or 2, node-negative, estrogen-receptor-positive breast cancer patients.
authors.affiliation: Comprehensive Cancer Center, Desert Regional Medical Center, Palm Springs, California, USA.
authors.forename: David M
authors.initials: DM
authors.lastname: Hyams
mesh_terms: D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D005260:Female; D020869:Gene Expression Profiling; D023281:Genomics / Q000639:trends*; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D009367:Neoplasm Staging; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor